All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During SOHO 2019, Houston, US, the AML Global Portal were pleased to interview Dr John DiPersio from Washington University Medical School, St. Louis, US, about the susceptibility of acute myeloid leukemia (AML) disease to novel immunotherapies, such as CAR-T cells, DARTs, and BITEs. He describes the challenges in overcoming the suppressive environment of AML and the lack of specific targets on malignant myeloid cells. He proceeds with the update on clinical advances in immune-based therapies and outlining future directions.
Is AML a disease susceptible to novel immunotherapies, such as CAR-T, DARTs, and BITEs?
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox